Shanghai Haohai Biological Technology Valuation
Is 6826 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 6826 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 6826 (HK$26.55) is trading below our estimate of fair value (HK$129.37)
Significantly Below Fair Value: 6826 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6826?
Key metric: As 6826 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 6826's PE Ratio? | |
|---|---|
| PE Ratio | 13.2x |
| Earnings | CN¥430.21m |
| Market Cap | CN¥13.02b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4x |
| Enterprise Value/EBITDA | 19.6x |
| PEG Ratio | 0.8x |
Price to Earnings Ratio vs Peers
How does 6826's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 22.5x | ||
1530 3SBio | 7.3x | 14.6% | HK$13.1b |
2696 Shanghai Henlius Biotech | 15.3x | 7.3% | HK$11.4b |
6955 Shandong Boan Biotechnology | 61.5x | n/a | HK$4.1b |
1061 Essex Bio-Technology | 6x | n/a | HK$1.6b |
6826 Shanghai Haohai Biological Technology | 13.2x | 16.8% | HK$14.0b |
Price-To-Earnings vs Peers: 6826 is good value based on its Price-To-Earnings Ratio (13.2x) compared to the peer average (22.5x).
Price to Earnings Ratio vs Industry
How does 6826's PE Ratio compare vs other companies in the Asian Biotechs Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 6826 is good value based on its Price-To-Earnings Ratio (13.2x) compared to the Asian Biotechs industry average (30.8x).
Price to Earnings Ratio vs Fair Ratio
What is 6826's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 13.2x |
| Fair PE Ratio | 12.6x |
Price-To-Earnings vs Fair Ratio: 6826 is expensive based on its Price-To-Earnings Ratio (13.2x) compared to the estimated Fair Price-To-Earnings Ratio (12.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
China Shineway Pharmaceutical Group
HK$6.1b
An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.
2877
HK$8.13
7D
-3.3%
1Y
n/a
Innovent Biologics
HK$60.6b
A biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China.
1801
HK$37.10
7D
3.2%
1Y
-18.1%
Consun Pharmaceutical Group
HK$6.8b
Researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China.
1681
HK$8.57
7D
0.8%
1Y
86.7%